Navigation Links
Shengtai Pharmaceutical Expands International Sales Program
Date:10/30/2008

- Dedicated Sales Team Focused on Key Global Markets -

WEIFANG, Shandong, China, Oct. 30 /Xinhua-PRNewswire-FirstCall/ -- Shengtai Pharmaceutical, Inc. (OTC Bulletin Board: SGTI) ("Shengtai" or "the Company"), a leading manufacturer and distributor of high-quality, pharmaceutical grade glucose products in China, today announced that it has restructured its international sales team committed to broaden Shengtai's product sales into selected global markets.

The international sales team is an integral part of our existing sales department as the Company sees growth potential in the overseas markets. Currently, the Company has existing customers in over 70 countries. The new team assumes responsibilities of all aspects of the international sales include research, regulatory affairs, marketing and sales to ensure the successful introduction of the Company's health and other products into targeted international markets. Shengtai's pharmaceutical grade glucose products have wide application in hospitals, clinics and other health-related services.

Recently, the international sales team attended the Guangzhou International Fair and presented Shengtai's products. The response from potential customers at this conference was encouraging.

Shengtai recently received the "Good Manufacturing Practice" (GMP) certificate for its new glucose manufacturing facility. This new facility has an annual production capacity of 120,000 tons and when combined with the existing plant provides the Company with a total annual capacity up to 180,000 tons of glucose. The Company is commencing operations in stages and will gradually ramp up production to expand its offerings.

Mr. Qingtai Liu, Chairman and CEO of Shengtai Pharmaceutical, stated, "Our high-quality products combined with low-cost, state-of-the-art manufacturing provides competitive advantages. We believe these advantages and our new production capacity will allow us to increase exports in targeted international markets."

"The Chinese market continues to represent a good growth opportunity for us as the economy is growing at approximately 8% in 2008. Additionally, the Chinese government is implementing policies to enhance economic growth through revised banking regulations to aid smaller businesses and effect reforms in rural areas to increase personal wealth, " Mr. Liu concluded.

About Shengtai Pharmaceutical, Inc.

Shengtai Pharmaceutical, Inc. through its wholly-owned subsidiary Shengtai Holding, Inc. (SHI), a New Jersey corporation, and the Chinese operating company of Weifang Shengtai Pharmaceutical Co., Ltd., is a leading manufacturer and supplier of pharmaceutical grade glucose used for medical purposes, and the glucose and cornstarch products for the food and beverage industry and for industrial production in China. For more information about Shengtai Pharmaceutical, Inc., please visit http://www.shengtaipharmaceutical.com .

Safe Harbor Statement

Certain statements in this press release and oral statements made by the Company constitute forward-looking statements. These statements include, without limitation, statements regarding our ability to prepare the company for growth, the Company's planned capacity expansion in 2008 and predictions and guidance relating to the Company's future financial performance. We have based these forward-looking statements largely on our current expectations and projections about future events and financial trends that we believe may affect our financial condition, results of operations, business strategy and financial needs but they involve risks and uncertainties that could cause actual results to differ materially from those in the forward-looking statements, which may include, but are not limited to, such factors as unanticipated changes in product demand especially in the pharmaceutical industry, pricing and demand trends for the Company's products, changes to government regulations, risk associated with operation of the Company's new facilities, risk associated with large scale implementation of the company's business plan, the ability to attract new customers, ability to increase its product's applications, cost of raw materials, downturns in the Chinese economy, and other information detailed from time to time in the Company's filings and future filings with the United States Securities and Exchange Commission. Investors are urged to consider these factors carefully in evaluating the forward-looking statements herein and are cautioned not to place undue reliance on such forward-looking statements, which are qualified in their entirety by this cautionary statement. The forward-looking statements made herein speak only as of the date of this press release and the Company undertakes no duty to update any forward-looking statement to conform the statement to actual results or changes in the company's expectations.

For more information, please contact:

Shengtai Pharmaceutical, Inc.

Ms. Yiru Melody Shi

Chief Financial Officer

Tel: +1-949-468-7078

Email: shengtaicfo@hotmail.com

Grayling Global

Eddie Cheung

Investor Relations

Tel: +1-646-284-9414

Email: echeung@hfgcg.com


'/>"/>
SOURCE Shengtai Pharmaceutical, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Shengtai Pharmaceutical, Inc. Reports Third Quarter Results of Fiscal Year 2008
2. Shengtai Pharmaceutical, Inc. Announces Conference Call to Discuss Third Quarter Results of Fiscal Year 2008
3. Shengtai Pharmaceutical, Inc. Reports Strong Second Quarter Results of Fiscal Year 2008
4. Shengtai Pharmaceutical, Inc. to Present at Roth Conference
5. Shengtai Pharmaceutical, Inc. to Present at Roth Capital Phoenix Conference
6. Shengtai Pharmaceutical, Inc. Reports First Quarter Results of Fiscal Year 2008
7. Shengtai Pharmaceutical, Inc. Reports Record 2007 Annual Results
8. MiddleBrook Pharmaceuticals Schedules Conference Call and Webcast for Third Quarter 2008 Financial Results
9. The Quigley Corporation Reports Third Quarter 2008 Results; Continues Investment in Pharmaceutical R&D Future
10. ISTA Pharmaceuticals Reports Third Quarter 2008 Financial Results
11. ADVENTRX Pharmaceuticals to Report Third Quarter 2008 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/24/2017)... ... March 24, 2017 , ... ... countries to hospitals in the United States, it’s a threat that is constantly ... obstacles facing infection prevention and offers strategies for the healthcare community to help ...
(Date:3/24/2017)... ... ... According to a new study by NCPA Senior Fellow John R. Graham, "the ... has directed the CBO to follow. The CBO itself previously recognized Obamacare would kill ... a reduction in employer-based coverage due to the GOP reform, which is not plausible. ...
(Date:3/24/2017)... ... March 24, 2017 , ... ... and related services to families and business owners across eastern Michigan, is connecting ... regional families struggling with financial difficulties. , The Oxford/Orion FISH Food Pantry works ...
(Date:3/24/2017)... ... March 24, 2017 , ... As the standards ... a communications platform that positions them as the go-to thought leader in all ... online publication as an always-on, always-fresh news, views and advocacy engine, called ONS ...
(Date:3/24/2017)... ... March 24, 2017 , ... The law firm of ... is pleased to announce Westchester resident Lauren C. Enea has joined the firm as ... firm, will concentrate her practice in elder law, Medicaid planning and applications, and Wills, ...
Breaking Medicine News(10 mins):
(Date:3/24/2017)... Research and Markets has announced the addition of the "Global ... ... very strong with a total of 97 drug candidates. Pharma giant such ... involved in the development of the IPF therapeutics. The IPF pipeline comprised ... 15 are in Phase II stage, 12 are in Phase I stage, ...
(Date:3/24/2017)... India , March 24, 2017 ... of the industry including definitions, classifications, applications and industry ... the international market including development history, competitive landscape analysis, ... ... Ampoules industry spread across 105 pages providing 10 company ...
(Date:3/24/2017)... , March 24, 2017  GenomeDx Biosciences today ... Information Database) and Decipher® Prostate Cancer Classifier tests will ... Association of Urology (EAU) Congress held March 24 to ... The Annual EAU Congress is Europe,s ... comprehensive research in the urological field. The ...
Breaking Medicine Technology: